Table 1.
Pooled proportions of metastatic recurrence rates in women diagnosed with breast cancer by median follow-up
| Median follow-up time | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1–4 years | 5–9 years | 10 + years | Total | |||||
| Studies (n) | Pooled proportion (95% CI) | Studies (n) | Pooled proportion (95% CI) | Studies (n) | Pooled proportion (95% CI) | Studies (n)a | Pooled proportion (95% CI) | |
| Overall | 95 | 12.2 (10.5–14.0) | 88 | 14.3 (12.9–15.7) | 13 | 23.3 (20.1–26.8) | 190 | 13.9 (12.8–15.1) |
| Source setting | ||||||||
| Hospital | 91 | 12.2 (10.3–14.2) | 78 | 15.3 (13.7–16.9) | 7 | 23.8 (18.2–29.8) | 171 | 14.1 (12.8–15.5) |
| PBCR | 5 | 12.2 (7–18.8) | 5 | 8.4 (6.8–10) | 5 | 22.7 (18.9–26.7) | 15 | 13.6 (10.4–17.2) |
| Other | 0 | – | 7 | 10.0 (5.7–15.4) | 1 | – | 7 | 10.0 (5.7–15.4) |
| Region | ||||||||
| Africa | 5 | 26.4 (16.7–37.4) | 1 | – | 0 | – | 6 | 21.7 (11.7–33.8) |
| Asia | 39 | 11.8 (9.2–14.7) | 43 | 16.1 (13.9–18.4) | 2 | – | 80 | 14.6 (12.6–16.7) |
| Europe | 17 | 11.0 (8.5–13.7) | 31 | 13.2 (11.4–15) | 9 | 21.9 (19–24.9) | 55 | 13.8 (12.1–15.7) |
| North America | 29 | 10.2 (6.7–14.3) | 10 | 7.7 (4.8–11.2) | 2 | – | 41 | 10.2 (7.5–13.2) |
| Oceania | 2 | – | 2 | – | 0 | – | 4 | 17.9 (10–27.5) |
| South America | 3 | 22.6 (20.7–24.6) | 1 | – | 0 | – | 4 | 31.5 (18.9–45.6) |
| Calendar year of diagnosis | ||||||||
| Until 1999 | 1 | – | 3 | 22.2 (15.6–29.6) | 2 | – | 6 | 22.2 (15.1–30.3) |
| From 2000 onwards | 89 | 11.8 (9.9–13.7) | 73 | 13.9 (12.3–15.5) | 4 | 18.0 (14.8–21.5) | 161 | 12.8 (11.7–14.0) |
| Stage at diagnosis | ||||||||
| Early (I–IIa) | 6 | 4.8 (2.5–7.8) | 6 | 6.6 (3.8–10.0) | 1 | – | 13 | 5.9 (4.3–7.7) |
| Locally advanced (IIb–IIIc) | 6 | 33.2 (24.7–42.3) | 4 | 35.0 (29.4–40.7) | 4 | 35.3 (28.9–42) | 13 | 34.5 (30.3–38.9) |
| Hormone receptor status | ||||||||
| HR+ | 11 | 9.6 (6.2–13.6) | 13 | 10.0 (7.5–12.7) | 3 | 13.4 (8.5–19.2) | 25 | 9.9 (8.0–11.9) |
| HR− | 24 | 15.3 (12.1–18.8) | 13 | 22.4 (15.8–29.7) | 3 | 40.5 (11.4–73.7) | 39 | 17.7 (15.0–20.7) |
| Age group | ||||||||
| < 50 years | 9 | 16.1 (10.8–22.1) | 14 | 19.7 (15.9–23.9) | 5 | 20.6 (15.6–26.0) | 27 | 18.6 (15.9–21.4) |
| 50–69 years | 1 | – | 2 | – | 3 | 15.7 (12.4–19.3) | 5 | 10.9 (9.0–12.9) |
| 70+ years | 1 | – | 0 | – | 2 | – | 3 | 13.3 (9.2–18.0) |
aStudies do not always sum to the total due to exclusion of studies from the same city or hospital to avoid overlapping or duplicating when combining groups. Meta-analyses were performed when more than 3 studies were available